AOP Health Shines a Light on the Silent Burden of Venous Leg Ulcers
For the press release click here
At the DGPL Congress, AOP Health and RHEACELL present a strategic alliance that boosts Europe's health sovereignty—through investment in research, production, and access to innovative therapies.
For the press release click here
RHEACELL and AOP Health have formed a new strategic partnership to deliver breakthrough therapies for the "butterfly children's" disease and chronic venous wounds.
https://www.aop-health.com/global_en/press/press-releases/rheacell-aop-health-strategic-partnership/
RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe.
For the press release click here
For the press release click here
Fantastic news! The first study center for our pivotal phase III study on therapy-resistant chronic venous ulcers has now officially been activated! We are thrilled to have Mark Whiteley as the Principal Investigator, and we are excited that The Whiteley Clinic is now part of this important study.
A huge thank you to FGK Clinical Research GmbH for their invaluable support in bringing this project to life!
For the press release click here
The article outlines that this is Argentina's first study involving stem cell therapy, marking a significant milestone for the country. It also highlights the treatment of the first patient and informs that they plan to enroll at least 15 more patients in the study.
Therapies with human stem cells for chronic venous leg ulcers ("open leg").
You can find the video summary HERE.
Source: German Dermatological Society e.V. (DDG) - https://derma.de/presse
RHEACELL receives positive signal for accelerated stem cell development program in rare "Butterfly Disease".
For the press release click here
RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected.
For the press release click here
Professor Dr. med. Karin Scharffetter-Kochanek, Dr. Christoph Ganss and Dr. Andreas Kluth from RHEACELL received the "Kooperationspreis Wissenschaft-Wirtschaft 2022" from Ulm University.
For the press release click here (only in German)
RHEACELL receives "Partners in Progress Award" from debra of America for Epidermolysis Bullosa research.
For the press release click here
It is only the second authorized "Somatic Cell Therapy Medicinal Product".
For more information click here
RHEACELL is conducting a follow-up study with highly purified stem cells for the treatment of previously incurable chronic ulcers.
For the press release click here
RHEACELL has been granted national marketing authorization in Germany (§ 4b of the German Medicinal Products Act) for its’ cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.
For the press release click here
The European Medicines Agency (EMA) has approved the pediatric investigation plan for our Epidermolysis Bullosa program, bringing us one step closer to filing for marketing authorization.
Based on convincing clinical results (I/IIa) in the indication of non-healing chronic venous ulcers (CVU), RHEACELL filed for national marketing authorization in Germany (special provisions governing advanced therapy medicinal products).
Heidelberg-based biopharmaceutical company demonstrates efficacy and safety of ABCB5-positive stem cells in CVU patients in clinical phase IIa trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Biopharma company completes three registered somatic cell therapy clinical trials for severe, chronic diseases.
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the FDA and the European Medicines Agency) and Fast Track Designation from the FDA for the treatment of LSCD.
You will find more scientific papers by following this link.